South Rampart Pharma Successfully Completes Phase 1 Study and Expands Phase 2 Plans to Include Neuropathic and Acute Pain Trials

Phase 1 data demonstrate that SRP-001 exhibits an exceptionally strong safety and robust pharmacokinetic profile and is well-tolerated Well-designed Phase 2 trials set to show statistical significance compared to placebo and positive control NEW ORLEANS, Jan. 2, 2024 /PRNewswire/ — South…